Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Jane L. Roberts"'
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
GZ17-6.02 is undergoing clinical evaluation in solid tumors and lymphoma. We defined the biology of GZ17-6.02 in prostate cancer cells and determined whether it interacted with the PARP1 inhibitor olaparib to enhance tumor cell killing. GZ17-6.02 int
Externí odkaz:
https://doaj.org/article/3573b92758b84eecb29e3a3dfd3deca6
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
We have extended our analyses of HDAC inhibitor biology in sarcoma. The multi-kinase inhibitor axitinib interacted with multiple HDAC inhibitors to kill sarcoma cells. Axitinib and HDAC inhibitors interacted in a greater than additive fashion to inac
Externí odkaz:
https://doaj.org/article/5ff1f49d5e3c41198e86b3f06d7ce526
Autor:
Martial Caillaud, Danielle Thompson, Wisam Toma, Alyssa White, Jared Mann, Jane L. Roberts, John W. Bigbee, David A. Gewirtz, M. Imad Damaj
Publikováno v:
Pharmaceutics, Vol 14, Iss 6, p 1296 (2022)
Paclitaxel is widely used in the treatment of various types of solid malignancies. Paclitaxel-induced peripheral neuropathy (PIPN) is often characterized by burning pain, cold, and mechanical allodynia in patients. Currently, specific pharmacological
Externí odkaz:
https://doaj.org/article/26598607bfdb40e3aeb66f4681b60b21
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Externí odkaz:
https://doaj.org/article/d9e04d01b2ed4c839ca8f0cf7278e1af
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Previously we demonstrated that the multiple sclerosis drug dimethyl fumarate (DMF) and its plasma breakdown product MMF could interact with chemotherapeutic agents to kill both GBM cells and activated microglia. The trial NCT02337426 demonstrated th
Externí odkaz:
https://doaj.org/article/417ae753fd424a9f9a2248b690dd7c36
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Sarcomas are a diverse set of malignancies. For soft tissue sarcomas, the kinase and chaperone inhibitor pazopanib is a standard of care therapeutic. Previously, we demonstrated that HDAC inhibitors enhanced pazopanib lethality against sarcoma and ot
Externí odkaz:
https://doaj.org/article/b98560037b724e398d2b44ad331bddaa
Autor:
Paul Dent, Laurence Booth, Jane L. Roberts, Andrew Poklepovic, Jennifer Martinez, Derek Cridebring, Eric M. Reiman
Publikováno v:
Aging. 14(20)
We defined the mechanisms by which the chaperone ATPase inhibitor AR12 and the multi-kinase inhibitor neratinib interacted to reduce expression of Tau and amyloid-precursor protein (APP) in microglia and neuronal cells. AR12 and neratinib interacted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::671763cf7095252c3ec8710541a42a5b
https://pubmed.ncbi.nlm.nih.gov/36227739
https://pubmed.ncbi.nlm.nih.gov/36227739
Autor:
Yasmin Alkhlaif, Katherine M. Contreras, Nipa H. Patel, Martial Caillaud, Mackinsey J Wood, M. Imad Damaj, Alyssa White, David A. Gewirtz, Wisam Toma, Jane L. Roberts, Asti Jackson, Tammy H Tran, Justin L. Poklis
Publikováno v:
Brain Behav Immun
Background and purpose Paclitaxel, a widely used anti-cancer drug, is frequently associated with prolonged and severe peripheral neuropathies (PIPN), associated with neuroinflammation. Currently, PIPN effective treatments are lacking. Peroxisome Prol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1417ec1dd506cc69fd01e35f89865038
https://doi.org/10.1016/j.bbi.2021.01.004
https://doi.org/10.1016/j.bbi.2021.01.004
Autor:
Paul Dent, Laurence Booth, Jane L. Roberts, Andrew Poklepovic, Jennifer Martinez, Derek Cridebring, Eric Reiman
Background We defined the mechanisms by which the chaperone ATPase inhibitor AR12 and the multi-kinase inhibitor neratinib interacted to reduce expression of Tau and amyloid-precursor protein (APP) in microglia and neuronal cells. Methods In vitro ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::780d4192751da750ed2a31e8a9e69d26
https://doi.org/10.21203/rs.3.rs-1441274/v1
https://doi.org/10.21203/rs.3.rs-1441274/v1
Publikováno v:
Semin Cancer Biol
The molecular mechanisms by which tumor cells survive or die following therapeutic interventions are complex. There are three broadly defined categories of cell death processes: apoptosis (Type I), autophagic cell death (Type II), and necrosis (Type
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a4eef040523646d375b994549a713dd
https://doi.org/10.1016/j.semcancer.2019.10.013
https://doi.org/10.1016/j.semcancer.2019.10.013